Loading…
Leading Chinese maker of recombinant human growth hormone (rhGH) and other biologic drugs.
Leading Chinese maker of recombinant human growth hormone (rhGH) and other biologic drugs.
In one line: A Chinese Genentech/Novo Nordisk for growth hormone.
Moat: narrow (regulatory licence, brand, scale). Long-standing leadership and manufacturing scale in China's growth-hormone market.
Headquarters: Hefei, Anhui, China · Employees: 2,505
Size Anhui Anke Biotechnology (Group) (300009.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.01B, the 1257th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.01 on 6 Nov 2026.
Performance Over six months the shares fell 9.4%, against +1.9% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 9.4% over the last twelve months (peer median +9.4%); the operating margin is 30.0% (peer median 15.0%).
Valuation It trades at 19.3× forward earnings against a peer median of 23.3× (10th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.0 points above its cost of capital (9.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.34B | CN¥2.63B | CN¥2.52B | CN¥2.85B | CN¥2.32B |
| Revenue growth | — | +4% | -11% | +23% | — |
| Gross profit | CN¥1.82B | CN¥1.95B | CN¥1.91B | CN¥2.19B | CN¥1.77B |
| EBITDA | n/a | CN¥912M | CN¥863M | CN¥1.01B | CN¥872M |
| Net income | CN¥652M | CN¥735M | CN¥707M | CN¥847M | CN¥703M |
| Free cash flow | CN¥551M | CN¥760M | CN¥607M | CN¥790M | CN¥251M |
| Capital expenditure | CN¥152M | CN¥127M | CN¥117M | CN¥195M | CN¥474M |
| Total debt | CN¥94.6M | CN¥76.1M | CN¥152M | CN¥262M | CN¥208M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Anhui Anke Biotechnology (Group) 300009.SZ | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% |
| Changchun High-Tech Industry (Group) 000661.SZ | $4.51B | -13% | -18% | -1% | 30.2× | 32.2% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
| Merck KGaA MRK.DE | $72.5B | +23% | 0% | 20% | 17.5× | 7.7% |
| Ascendis Pharma A/S ASND | $16.0B | +8% | +128% | 10% | 40.8× | 36.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300009.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.4% | -0.8% | 10th lowest of 21 |
| 6-month return | -9.4% | +1.9% | 10th lowest of 21 |
| Distance from 52-week high | -30.5% | -25.3% | 10th lowest of 21 |
| Revenue growth (TTM) | -9.4% | +9.4% | 4th lowest of 21 |
| Operating margin | 30.0% | 15.0% | 4th highest of 21 |
| Forward P/E | 19.3× | 23.3× | 10th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 9.1% | 6.0% | 9th most demanding of 18 |
| Growth delivered (Del g) | +9.3% | +8.0% | 7th highest of 18 |
| Hurdle (Req g minus delivered) | -0.2 pp | -3.1 pp | 9th most demanding of 18 |
| ROIC minus cost of capital | +10.0 pp | +0.0 pp | 6th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |